Previous 10 | Next 10 |
Cannabics Pharma ([[CNBX]] +9.7%) has obtained positive interim results for its ongoing in-vivo study evaluating the efficacy of the company's RCC-33 for colorectal cancer in nude-mice.The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison ...
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, Feb. 3, 2021 /PRNewswire/ -...
Cannabis sales are determined by number of dispensaries and the availability to them by proximity. California has no restrictions regarding the number of dispensaries such as Washington State. Growth in cannabis in California will eclipse the entire cannabis industry's current ret...
Cannabis companies are starting to turn a profit and print positive EPS. Here are the few that are earning a profit. Many companies are close to turning a positive EPS. The industry itself is expected to expand some 100% in the next couple of years, and with economies of scale, th...
Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, Dec. 21, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the deve...
The cannabis industry has sold off significantly over the past 12-18 months, leaving some stocks significantly undervalued on a book/price metric. Cannabis stocks are starting to push upwards again as some companies near profitability and certain metrics will provide information for i...
Cannabics Pharmaceuticals ([[CNBX]] -1.3%) announces that its has established a subsidiary, Digestix Bioscience Inc., dedicated to the development of medical devices and pharmaceutical compositions for the treatment of precancerous and early stage neoplastic local tumors.The new company is fo...
Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors PR Newswire TEL AVIV, Israel and BETHESDA, Maryland, Nov. 16, 2020 TEL AVIV , Israel and BETHESDA, Marylan...
Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33 PR Newswire TEL AVIV, Israel and BETHESDA, Md., Nov. 9, 2020 TEL AVIV , Israel and BETHESDA, Md., ...
Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application PR Newswire TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 TEL AVIV , Israel a...
News, Short Squeeze, Breakout and More Instantly...
Cannabics Pharmaceuticals Inc Company Name:
CNBX Stock Symbol:
OTCMKTS Market:
Cannabics Pharmaceuticals Inc Website:
CNBX Pharmaceuticals Inc (CNBX) is expected to report for Q1 2003
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma PR Newswire REHOVOT, Israel and BETHESDA, MD , Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader i...
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy PR Newswire REHOVOT, Israel and BETHESDA, MD. , Oct. 18, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of...